Hormonal therapy without chemotherapy | Competing risk regression for iLRR | 60-month cumulative incidence of iLRR (95% CI) | |
---|---|---|---|
HR (95% CI) | Ptrend | ||
RS < 18 | 1.0 (reference) | 0.02 | 1.2% (0.5–2.8%) |
RS 18–24 | 1.66 (0.59–4.66) | 3.7% (1.5–7.7%) | |
RS 25–30 | 3.59 (0.78–16.6) | 7.3% (1.0–22.7%) | |
RS ≥31 | 7.05 (0.97–51.3) | 33.3% (0.9–77.4%) |